Literature DB >> 11408922

Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer.

B Nakata1, S Nishimura, T Ishikawa, M Ohira, H Nishino, J Kawabe, H Ochi, K Hirakawa.   

Abstract

18Fluorine-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) is a unique imaging diagnostic tool to evaluate glucose metabolism and hexokinase activity which may reflect the aggressiveness of a tumor. Thirty-seven patients with primary pancreatic cancer were evaluated with 18F-FDG-PET. Thirteen patients underwent resection for the pancreatic cancer and 24 patients had unresectable tumors. The standardized uptake values (SUV) of 18F-FDG in the primary tumors were calculated. No correlations were found between the SUV in the tumors and the metastatic status to the peritoneal/liver, TNM factors/stage, or resectability. The patients were divided into 2 groups with high and low SUV, with the cut-off value being 3.0 (median SUV value of 37 cases). No differences in the probability of survival were observed between the 2 groups in the patients with resectable tumors. However, in the patients with unresectable tumors, those in the high SUV group had a significantly shorter prognosis than those in the low SUV group. Moreover, a multivariate analysis of survival indicated that SUV is an independent prognostic factor for patients with unresectable pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408922     DOI: 10.3892/ijo.19.1.53

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.

Authors:  Zhen Wang; Jun-Qiang Chen; Jin-Lu Liu; Xin-Gan Qin; Yuan Huang
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

2.  PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG.

Authors:  Anu Autio; Tiina Ujula; Pauliina Luoto; Satu Salomäki; Sirpa Jalkanen; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-04       Impact factor: 9.236

3.  Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer.

Authors:  Jae Pil Hwang; Ilhan Lim; Kyoung Jin Chang; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2012-06-30

Review 4.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

5.  Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Authors:  Hua-Xiang Xu; Tao Chen; Wen-Quan Wang; Chun-Tao Wu; Chen Liu; Jiang Long; Jin Xu; Ying-Jian Zhang; Run-Hao Chen; Liang Liu; Xian-Jun Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-13       Impact factor: 9.236

6.  Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.

Authors:  Andrej Lyshchik; Tatsuya Higashi; Yuji Nakamoto; Koji Fujimoto; Ryuichiro Doi; Masayuki Imamura; Tsuneo Saga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

7.  18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma.

Authors:  Jeong Won Lee; Keon Wook Kang; Sung-Hye Park; Sang Mi Lee; Jin Chul Paeng; June-Key Chung; Myung Chul Lee; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-18       Impact factor: 9.236

8.  Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer.

Authors:  Hisao Wakabayashi; Yoshihiro Nishiyama; Tsuyoshi Otani; Takanori Sano; Shinichi Yachida; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

9.  Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.

Authors:  Jian-Guo Zhao; Ya Hu; Quan Liao; Zhe-Yu Niu; Yu-Pei Zhao
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

10.  Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer.

Authors:  Hirotada Kittaka; Hidenori Takahashi; Hiroaki Ohigashi; Kunihito Gotoh; Terumasa Yamada; Yasuhiko Tomita; Yoshihisa Hasegawa; Masahiko Yano; Osamu Ishikawa
Journal:  World J Surg       Date:  2013-01       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.